Despite the anti-leukemic activity of EGFR inhibitors, AML cell lines do not express EGFR (3, 4, 6, 24, 31), implying that gefitinib and erlotinib may act via EGFR-independent mechanisms in this malignancy. The gene discussed is EGFR; the disease is acute myeloid leukemia.